Related Experiment Video
Updated: Jan 29, 2026

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
Published on: October 10, 2025
Identification of Genomic Alterations Acquired During Treatment With EGFR-TKIs in Non-small Cell Lung Cancer
Naoki Kubo1,2, Taishi Harada3,4, Yoshimasa Shiraishi1,5
1Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Background/Aim:
Patients with non-small cell lung cancer (NSCLC) treated with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) eventually develop resistance to these drugs. Although various mechanisms of such resistance have been identified, the mechanism in many cases remains unknown.
Materials And Methods:
Whole-exome sequencing was performed for tumor tissue from 15 patients with NSCLC who developed EGFR-TKI resistance. Tumor specimens obtained before EGFR-TKI treatment were also analyzed for four patients and normal white blood cell samples for six patients in order to detect genomic alterations that occurred during treatment.
Results:
The mutational signature and mutational load acquired during EGFR-TKI treatment varied among patients, with common EGFR-TKI resistance mechanisms including the T790M secondary mutation of EGFR and MET amplification being acquired together with many other genomic alterations. Our results provide insight into the mutational landscape acquired during the development of EGFR-TKI resistance in NSCLC.
Insights
Acquired genomic alterations drive resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC). Understanding these changes, like T790M mutations and MET amplification, is key to overcoming treatment resistance.
Area of Science:
- Oncology
- Genomics
- Molecular Biology
Background:
- Non-small cell lung cancer (NSCLC) patients treated with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) often develop drug resistance.
- The precise mechanisms underlying EGFR-TKI resistance remain incompletely understood in many cases.
Purpose of the Study:
- To investigate the genomic landscape of acquired resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer.
- To identify novel genomic alterations associated with the development of EGFR-TKI resistance.
Main Methods:
- Whole-exome sequencing was performed on tumor tissue from 15 NSCLC patients who developed acquired resistance to EGFR-TKIs.
- Genomic alterations occurring during treatment were analyzed by comparing pre-treatment tumor samples (n=4) and normal white blood cell samples (n=6) with post-treatment tumor tissues.
Main Results:
- Significant inter-patient variability was observed in mutational signatures and mutational load acquired during EGFR-TKI treatment.
- Common resistance mechanisms identified include the T790M secondary mutation in EGFR and MET amplification.
- Numerous other genomic alterations were acquired concurrently with known resistance mechanisms, highlighting a complex mutational landscape.
Conclusions:
- The development of EGFR-TKI resistance in NSCLC is characterized by a diverse array of acquired genomic alterations.
- Identifying these acquired mutations and amplifications provides crucial insights into resistance mechanisms.
- Further research into these genomic changes may lead to strategies to overcome or prevent EGFR-TKI resistance in NSCLC.
Related Concept Videos
Genomics
Treatment Resistant Cancers
Alterations in Respiration II
In Biot's breathing, the respiratory rate and depth are irregular, alternating between periods of deep gasping and apnea. Common causes...
Altered States of Awareness
The ingestion of substances like stimulants or hallucinogens leads to chemical alterations in the brain...
Lung Capacity
Genomic Imprinting and Inheritance
The expression of some genes depends on which parent passed the gene to the offspring, through a phenomenon known as...

